InvestorsHub Logo
Followers 40
Posts 7682
Boards Moderated 1
Alias Born 01/04/2006

Re: None

Wednesday, 11/09/2011 10:41:29 AM

Wednesday, November 09, 2011 10:41:29 AM

Post# of 506
Sinovac Biotech reports positive preliminary phase II clinical trial results for EV71 vaccine against hand, foot and mouth disease (SVA) 2.35 : The preliminary phase II results for the EV71 vaccine showed a good immunogenicity and a favorable safety profile with no vaccine-related serious adverse event. The purpose for the phase III clinical trial is to evaluate the efficacy of protection against HFMD caused by EV71.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SVA News